Get the Stockscreener App
39.19
1.99%
0.66
Apogee Therapeutics Inc stock is traded at $39.19, with a volume of 166.43K.
It is up +1.99% in the last 24 hours and up +8.37% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$38.53
Open:
$38.95
24h Volume:
166.43K
Relative Volume:
0.30
Market Cap:
$2.28B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-14.23
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+10.88%
1M Performance:
+8.37%
6M Performance:
-23.52%
1Y Performance:
-43.70%
1-Day Range:
$38.02
$40.03
1-Week Range:
$35.13
$41.87
52-Week Range:
$29.26
$71.75
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.19 | 2.28B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.61 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.70 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.12 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.17 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.50 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World
Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
TD Cowen reiterates buy on Apogee Therapeutics stock By Investing.com - Investing.com UK
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com India
Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World
New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World
Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position - TipRanks
Where are the Opportunities in (APGE) - Stock Traders Daily
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments - TipRanks
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB - Defense World
Apogee Therapeutics (NASDAQ:APGE) Receives “Outperform” Rating from Wedbush - Defense World
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewswire
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy - Investing.com India
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy By Investing.com - Investing.com South Africa
Apogee Therapeutics price target raised to $116 from $110 at Guggenheim - TipRanks
Apogee Therapeutics Reports Positive Phase 1 Results - TipRanks
Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990 - Marketscreener.com
Apogee Therapeutics Full-Year Loss Widens -March 03, 2025 at 06:56 am EST - Marketscreener.com
Apogee Therapeutics, Inc. SEC 10-K Report - TradingView
Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial - Marketscreener.com
Apogee Therapeutics Advances Clinical Pipeline for APG777 and APG279, Reports Strong Cash Position and 2024 Financial Results - Nasdaq
Can Apogee's Overenrolled Clinical Trial Fast-Track Its Challenge to DUPIXENT? - StockTitan
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy - The Bakersfield Californian
Apogee Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire
Could Apogee's New Antibody End Monthly Injections for Chronic Inflammation Patients? - StockTitan
Rhumbline Advisers Has $2.39 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average PT from Analysts - Defense World
Apogee Therapeutics (APGE) to Release Earnings on Tuesday - Defense World
Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average Target Price from Brokerages - MarketBeat
Apogee Therapeutics to Host Conference Call to Report - GlobeNewswire
Can Apogee's APG990 Clinical Data Transform Its Inflammatory Disease Pipeline? - StockTitan
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week LowHere's Why - MarketBeat
1 Biotech Stock to Buy in 2025, and 1 to Avoid - AOL
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. - AOL
Apogee Therapeutics (APGE) Projected to Post Earnings on Tuesday - MarketBeat
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs - AOL
Apogee Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewswire
How Will Apogee Therapeutics Address Investors at March Healthcare Conferences? - StockTitan
(APGE) Trading Report - Stock Traders Daily
Interesting APGE Put And Call Options For October 17th - Nasdaq
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apogee Therapeutics Inc Stock (APGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
Mar 05 '25 |
Sale |
30.15 |
10,000 |
301,511 |
1,292,987 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):